Dr. Roland Griffiths is a pioneer in psychopharmacology research, having worked for over 40 years with mood-altering substances. Nearly two decades ago, Dr. Griffiths created the psilocybin research program at Johns Hopkins University.
Most recently his research demonstrated that high-dose synthetic psilocybin, when administered in a safe and clinical setting under the guidance of a team of professionals, was able to have a lasting effect on depression and anxiety in patients with life-threatening cancer mediated through mystical experiences that have a phenomenology and psychometric pattern that corresponds to the same sort of religious or mystical experiences documented throughout human history.
In addition to this most recent research, however, Dr. Griffiths has also done research on: the effects it can have on the so-called personality domain of openness, its effects in beginning and long-term meditators, and the effects it has on enhancing smoking cessation. He’s been a part of brain imaging studies and explored its pharmacological and neural mechanisms of action and conducted surveys on so-called “bad trips”, as well as looked at drug interactions.
This was a dense one, thank god for notes!Read More